Meeting
2024 ASCO Gastrointestinal Cancers Symposium
A phase 2 study of fruquintinib in combination with S-1 for second-line treatment of esophageal squamous cell carcinoma after first-line immunotherapy failure.
Authors
Ningning Li
Peking Union Medical College Hospital, Beijing, China
Ningning Li , Yuping Ge , Xiang Wang , Wei Qiu , Zhiyang Zhang , Na Zhou , Lin Zhao
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05636150
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 323)
DOI
10.1200/JCO.2024.42.3_suppl.323
Abstract #
323
Poster Bd #
F3
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Efficacy and safety of fruquintinib plus investigator's choice of chemotherapy as second-line therapy in metastatic colorectal cancer: A multicenter, single-arm phase 2 trial.
First Author: Wensi Zhao
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Clinical outcomes for IDH1 mutant biliary tract cancer (BTC) treated with contemporary systemic therapy.
First Author: Darren Cowzer
Poster
2021 ASCO Annual Meeting
A randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib (2ND-STEP, JCOG1802).
First Author: Makoto Endo
Poster
2021 Gastrointestinal Cancers Symposium
Phase II study of anlotinib plus sintlimab as second-line treatment for patients with advanced biliary tract cancers.
First Author: Hong Zong